This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AmerisourceBergen (ABC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 7.69% and 0.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Stock Moves -1%: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $60.63 in the latest trading session, marking a -1% move from the prior day.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Cardinal Health (CAH) to Extend Medical Distribution Presence
by Zacks Equity Research
Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.
Zacks Industry Outlook Highlights McKesson, West Pharmaceutical Services and Cardinal Health
by Zacks Equity Research
McKesson, West Pharmaceutical Services and Cardinal Health have been highlighted in this Industry Outlook article.
3 Lucrative Stocks From the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic-induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Cardinal Health (CAH) Unveils the First Surgical Incise Drape
by Zacks Equity Research
Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.
Should Value Investors Pick Cardinal Health (CAH) Stock Now?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
Cardinal Health (CAH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $52.61 in the latest trading session, marking a +0.08% move from the prior day.
Cardinal Health (CAH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 3.25% and 1.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $52.63 in the latest trading session, marking a +0.61% move from the prior day.
Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Broadcom and Cardinal Health have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Broadcom and Cardinal Health have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Cardinal Health (CAH)
by David Bartosiak
Earnings are not as healthy as they could be.
New Strong Sell Stocks for January 12th
by Zacks Equity Research
ASH, CAH, and ESTA have been added to the Zacks Rank #5 (Strong Sell) List on January 12, 2022
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical and Cardinal Health
by Zacks Equity Research
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical and Cardinal Health